DERM NASDAQ
Journey Medical Corporation
1W: -2.2%
1M: +23.2%
3M: -26.9%
YTD: -16.6%
1Y: -9.7%
3Y: +314.0%
$5.96
-0.25 (-4.03%)
Weekly Expected Move ±12.6%
$5
$6
$6
$7
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (31)
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Journey Medical Corporation Q1 2026 Earnings Call Summary
Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals
Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings
Journey Medical (DERM) Q1 2026 Earnings Transcript
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Q1 EPS Estimates for Journey Medical Cut by HC Wainwright
HC Wainwright Raises Earnings Estimates for Journey Medical
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts
HC Wainwright Weighs in on Journey Medical Q1 Earnings
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
12 Health Care Stocks Moving In Thursday's Intraday Session
Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand
Journey Medical Non-GAAP EPS of $0.10, revenue of $61.6M misses by $3.05M
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Earnings Scheduled For March 25, 2026
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Analysts Set Journey Medical Corporation (NASDAQ:DERM) Target Price at $12.17
Journey Medical (NASDAQ:DERM) Shares Down 3.5% – What’s Next?
Journey Medical Corporation (NASDAQ:DERM) Receives $12.17 Consensus Target Price from Brokerages
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology